Piramal Pharma Marks Progress in Sustainability with Significant Emissions Reduction

Piramal Pharma Limited has reported a landmark year in its sustainability efforts, achieving a 22.6% decrease in Scope 1 and Scope 2 greenhouse gas emissions. This milestone is part of its Science Based Targets initiative (SBTi)-approved decarbonisation strategy. Additionally, renewable energy now accounts for 41% of the company's energy consumption.

In terms of quality and compliance, Piramal Pharma completed 38 regulatory inspections, including three by the USFDA, all without any Official Action Indicated (OAI) observations. The company also invested US$90 million to enhance capabilities at its Lexington and Riverview facilities.

Piramal Pharma is committed to community engagement, having invested ₹8.98 crore in CSR initiatives, positively impacting 1.8 million people. This focus on sustainability aims to create long-term value and build stronger communities.